HomeNews

Photocure ASA - Notification of trade

Published: 21 January 2010Financial Investment & Stock



 

Oslo, Norway, 21 January 2010.

 

As part of the share buy back program, Photocure has on 20 January 2010 bought 8,000 shares in Photocure ASA with an average price of NOK 46.49 per share. The company owns after this 393,458 shares in Photocure ASA.

 

 

 

For further information, contact:

Photocure ASA

Christian Fekete (CFO)

E-mail: cf@photocure.no

Mobile +47 916 42 938

 

Hoffsveien 48

NO-0377 Oslo, Norway
www.photocure.com

 
This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events

NEWS POST
test
Oslo, Norway
16 May 2023
NEWS POST
test
Oslo, Norway
8 February 2023
PRESS-RELEASE
New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement
Oslo, Norway
3 January 2023
NEWS POST
Bladder Cancer: New Meta-analysis
Oslo, Norway
15 December 2022
NEWS POST
Photocure Partner Asieris announces First Patient treated in Hexvix Real-world Evidence study in Hainan, China
Oslo, Norway
12 December 2022
NEWS POST
Photocure to participate in the NALSC and DNB Healthcare Conferences in December
Oslo, Norway
5 December 2022
PRESS-RELEASE
New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting
Oslo, Norway
5 December 2022
OSE Notice
Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting
Oslo, Norway
7 November 2022
PRESS-RELEASE
Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China
Oslo, Norway
4 November 2022
OSE Notice
Photocure ASA: Results for the third quarter of 2022
Oslo, Norway
2 November 2022
OSE Notice
Photocure ASA: Invitation to presentation of third quarter 2022 financial results
Oslo, Norway
25 October 2022
PRESS-RELEASE
Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC
Oslo, Norway
4 October 2022
PRESS-RELEASE
Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.
Oslo, Norway
28 September 2022
PRESS-RELEASE
New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia
Oslo, Norway
20 September 2022
PRESS-RELEASE
Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance
Oslo, Norway
15 September 2022
PRESS-RELEASE
Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology
Oslo, Norway
8 September 2022
GLOBAL HEADQUARTERS

Photocure ASA
Hoffsveien 4
0275 Oslo
Norway

E-mail: info@photocure.no
NORTH AMERICA

Photocure INC
202 Carnegie Center
Suite 101, Princeton,
NJ 08540, USA

E-mail: info@photocure.com
EUROPE

Photocure GmbH
Marc-Chagall-Str. 2
40477 Düsseldorf
Germany

E-mail: kontakt@photocure.com
Follow us
Privacy PolicyTerms of use
© Photocure 2024
Key InformationProviding an update on the XYZ incident

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do